The performance of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated here substantial wealth , the patent expiration in key markets has introduced significant risk . Investors are now assessing the effect of lower-cost